925 related articles for article (PubMed ID: 18668552)
1. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus.
Petri M; Stohl W; Chatham W; McCune WJ; Chevrier M; Ryel J; Recta V; Zhong J; Freimuth W
Arthritis Rheum; 2008 Aug; 58(8):2453-9. PubMed ID: 18668552
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of tumour necrosis factor family members a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BLyS) are inversely correlated in systemic lupus erythematosus.
Morel J; Roubille C; Planelles L; Rocha C; Fernandez L; Lukas C; Hahne M; Combe B
Ann Rheum Dis; 2009 Jun; 68(6):997-1002. PubMed ID: 18676986
[TBL] [Abstract][Full Text] [Related]
3. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
Petri MA; van Vollenhoven RF; Buyon J; Levy RA; Navarra SV; Cervera R; Zhong ZJ; Freimuth WW;
Arthritis Rheum; 2013 Aug; 65(8):2143-53. PubMed ID: 23754628
[TBL] [Abstract][Full Text] [Related]
4. B lymphocyte stimulator expression in pediatric systemic lupus erythematosus and juvenile idiopathic arthritis patients.
Hong SD; Reiff A; Yang HT; Migone TS; Ward CD; Marzan K; Shaham B; Phei WC; Garza J; Bernstein B; Stohl W
Arthritis Rheum; 2009 Nov; 60(11):3400-9. PubMed ID: 19877053
[TBL] [Abstract][Full Text] [Related]
5. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations.
Stohl W; Metyas S; Tan SM; Cheema GS; Oamar B; Xu D; Roschke V; Wu Y; Baker KP; Hilbert DM
Arthritis Rheum; 2003 Dec; 48(12):3475-86. PubMed ID: 14673998
[TBL] [Abstract][Full Text] [Related]
6. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response.
Cambridge G; Isenberg DA; Edwards JC; Leandro MJ; Migone TS; Teodorescu M; Stohl W
Ann Rheum Dis; 2008 Jul; 67(7):1011-6. PubMed ID: 17962238
[TBL] [Abstract][Full Text] [Related]
7. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus.
Feng X; Wu H; Grossman JM; Hanvivadhanakul P; FitzGerald JD; Park GS; Dong X; Chen W; Kim MH; Weng HH; Furst DE; Gorn A; McMahon M; Taylor M; Brahn E; Hahn BH; Tsao BP
Arthritis Rheum; 2006 Sep; 54(9):2951-62. PubMed ID: 16947629
[TBL] [Abstract][Full Text] [Related]
8. Elevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab.
Roth DA; Thompson A; Tang Y; Hammer AE; Molta CT; Gordon D
Lupus; 2016 Apr; 25(4):346-54. PubMed ID: 26385220
[TBL] [Abstract][Full Text] [Related]
9. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases.
Cheema GS; Roschke V; Hilbert DM; Stohl W
Arthritis Rheum; 2001 Jun; 44(6):1313-9. PubMed ID: 11407690
[TBL] [Abstract][Full Text] [Related]
10. Serum free light chains as biomarkers for systemic lupus erythematosus disease activity.
Aggarwal R; Sequeira W; Kokebie R; Mikolaitis RA; Fogg L; Finnegan A; Plaas A; Block JA; Jolly M
Arthritis Care Res (Hoboken); 2011 Jun; 63(6):891-8. PubMed ID: 21312346
[TBL] [Abstract][Full Text] [Related]
11. Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus.
Jacobi AM; Odendahl M; Reiter K; Bruns A; Burmester GR; Radbruch A; Valet G; Lipsky PE; Dörner T
Arthritis Rheum; 2003 May; 48(5):1332-42. PubMed ID: 12746906
[TBL] [Abstract][Full Text] [Related]
12. Anti-lipoprotein lipase antibodies: a new player in the complex atherosclerotic process in systemic lupus erythematosus?
de Carvalho JF; Borba EF; Viana VS; Bueno C; Leon EP; Bonfá E
Arthritis Rheum; 2004 Nov; 50(11):3610-5. PubMed ID: 15529371
[TBL] [Abstract][Full Text] [Related]
13. The reduction of serum B-lymphocyte activating factor levels following quinacrine add-on therapy in systemic lupus erythematosus.
Toubi E; Kessel A; Rosner I; Rozenbaum M; Paran D; Shoenfeld Y
Scand J Immunol; 2006 Apr; 63(4):299-303. PubMed ID: 16623930
[TBL] [Abstract][Full Text] [Related]
14. Anti-C1q antibodies and antiendothelial cell antibodies in systemic lupus erythematosus - relationship with disease activity and renal involvement.
Oelzner P; Deliyska B; Fünfstück R; Hein G; Herrmann D; Stein G
Clin Rheumatol; 2003 Oct; 22(4-5):271-8. PubMed ID: 14576989
[TBL] [Abstract][Full Text] [Related]
15. Hyperprolactinemia in males with systemic lupus erythematosus.
Mok CC; Lau CS; Lee KW; Wong RW
J Rheumatol; 1998 Dec; 25(12):2357-63. PubMed ID: 9858430
[TBL] [Abstract][Full Text] [Related]
16. Reticulocytes bearing C4d as biomarkers of disease activity for systemic lupus erythematosus.
Liu CC; Manzi S; Kao AH; Navratil JS; Ruffing MJ; Ahearn JM
Arthritis Rheum; 2005 Oct; 52(10):3087-99. PubMed ID: 16200588
[TBL] [Abstract][Full Text] [Related]
17. Correlation of the expression levels of BLyS and its receptors mRNA in patients with systemic lupus erythematosus.
Ju S; Zhang D; Wang Y; Ni H; Kong X; Zhong R
Clin Biochem; 2006 Dec; 39(12):1131-7. PubMed ID: 17069785
[TBL] [Abstract][Full Text] [Related]
18. Serum albumin as a marker for disease activity in patients with systemic lupus erythematosus.
Yip J; Aghdassi E; Su J; Lou W; Reich H; Bargman J; Scholey J; Gladman DD; Urowitz MB; Fortin PR
J Rheumatol; 2010 Aug; 37(8):1667-72. PubMed ID: 20516026
[TBL] [Abstract][Full Text] [Related]
19. Effect of disease activity and damage on quality of life in patients with systemic lupus erythematosus: a 2-year prospective study.
Mok CC; Ho LY; Cheung MY; Yu KL; To CH
Scand J Rheumatol; 2009; 38(2):121-7. PubMed ID: 18991189
[TBL] [Abstract][Full Text] [Related]
20. Elevated B lymphocyte stimulator levels are associated with increased damage in an Irish systemic lupus erythematosus cohort.
McCarthy EM; Lee RZ; Ní Gabhann J; Smith S; Cunnane G; Doran MF; Howard D; O'Connell P; Kearns G; Jefferies CA
Rheumatology (Oxford); 2013 Jul; 52(7):1279-84. PubMed ID: 23479724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]